Complete Genomics and Illumina Settle Patent Litigation

MOUNTAIN VIEW, Calif., July 18, 2013 /PRNewswire/ -- Complete Genomics, Inc. (formerly NASDAQ: GNOM) ("Complete"), a wholly-owned subsidiary of BGI-Shenzhen ("BGI"), a leading international genomics organization based in Shenzhen, China, today announced that it has entered into a settlement agreement with Illumina, Inc. under which Illumina will dismiss with prejudice both lawsuits it had brought against Complete:  Illumina, Inc. and Solexa, Inc. v. Complete Genomics, Inc., Case No. 10-cv-05542 EDL (N.D. Cal.); and Illumina, Inc. and Illumina Cambridge Ltd. v. Complete Genomics, Inc., Case No. 12-cv-01465 BEN BGS (S.D. Cal).  Complete will dismiss with prejudice all counterclaims.  The parties have entered into mutual releases, and each party will bear its own litigation costs.  No payment is being made by either party to the other, and no licenses are being granted by either party to the other.

"We are pleased to have reached a settlement with Illumina regarding this matter.  This resolution allows Complete to focus on its vision of revolutionizing medicine through the use of whole genome sequencing," Dr. Clifford Reid, CEO of Complete, said.

About Complete

Complete Genomics provides the most accurate whole human genome sequencing available today. The company's proprietary sequencing technology and advanced informatics and analysis software provide researchers and clinicians worldwide with the genomic information needed to better understand the prevention, diagnosis, and treatment of diseases. Additional information can be found at http://www.completegenomics.com.

SOURCE Complete Genomics, Inc.